Progress of anti-angiogenic therapy for brain tumors : new modality and resolution of the resistance

本研究旨在解决胶质母细胞瘤的耐药问题，寻找新一代的以胶质母细胞瘤内皮细胞为靶点的抗血管生成药物.胶质母细胞瘤的抗血管生成治疗方案：使用CPT-11的Metronomic治疗对胶质瘤生长有效，无全身副作用（J Neuro-oncology，2010）.建立了连续VEGF抗体治疗的胶质母细胞瘤复发小鼠模型（Brain Tumor Pathol 2010，J Oncology 2010）。在此模型中，CXCR 7特异性抑制剂CCX 771和SDF-1的抑制剂LMWH均能抑制VEGF抗体治疗后的复发。3.与单独接种肿瘤细胞相比，肿瘤内皮细胞和肿瘤细胞联合接种对胶质瘤的生长有更强的抑制作用。

This study was designed to resolve the resistance and find a new generation anti-angiogenic therapy targeting glioblastoma endothelial cells.1. Solution of anti-angiogenic treatment for glioblastoma : Metronomic treatment using CPT-11 was effective to glioma growth without systemic side effect (J Neuro-oncology, 2010).2. Glioblastoma recurrence mouse model with continuous VEGF antibody treatment was established (Brain Tumor Pathol 2010, J Oncology 2010). With this model, Specific CXCR7 inhibitor, CCX771 and LMWH, antagnosit of SDF-1, inhibited recurrence after VEGF antibody treatment.3.Vaccination with tumor endothelial cells and tumor cells inhibited glioma growth strongly compared to vaccination with tumor cell alone.